Baseline characteristics and factors associated with
nutritional and pulmonary status at enrollment in the cystic
fibrosis EPIC observational cohort.
Pediatric pulmonology
, 2010 Sep: 934-44
Changes in cystic fibrosis sputum microbiology in the
United States between 1995 and 2008.
Pediatric pulmonology
, 2010 Apr: 363-70
Return of FEV1 after pulmonary exacerbation in children
with cystic fibrosis.
Pediatric pulmonology
, 2010 Feb: 127-34
Association of socioeconomic status with the use of
chronic therapies and healthcare utilization in children with
cystic fibrosis.
The Journal of pediatrics
, 2009 Nov: 634-9.e1-4
Early anti-pseudomonal acquisition in young patients with
cystic fibrosis: rationale and design of the EPIC clinical trial
and observational study'.
Contemporary clinical trials
, 2009 May: 256-68
Pseudomonas aeruginosa Type III secretion system interacts
with phagocytes to modulate systemic infection of zebrafish
embryos.
Cellular microbiology
, 2009 Feb 6
Impact of Pseudomonas and Staphylococcus infection on
inflammation and clinical status in young children with cystic
fibrosis.
The Journal of pediatrics
, 2009 Feb: 183-8
Pseudomonas aeruginosa lasR mutants are associated with
cystic fibrosis lung disease progression.
Journal of cystic fibrosis : official journal of
the European Cystic Fibrosis Society
, 2009 Jan: 66-70
Oral corticosteroid therapy in cystic fibrosis patients
hospitalized for pulmonary exacerbation: a pilot study.
Chest
, 2007 Oct: 1212-8
Unique lipid a modifications in Pseudomonas aeruginosa
isolated from the airways of patients with cystic
fibrosis.
The Journal of infectious
diseases
, 2007 Oct 1: 1088-92
Duration of treatment effect after tobramycin solution for
inhalation in young children with cystic fibrosis.
Pediatric pulmonology
, 2007 Jul: 610-23
Selection for Staphylococcus aureus small-colony variants
due to growth in the presence of Pseudomonas aeruginosa.
Proceedings of the National Academy of Sciences
of the United States of America
, 2006 Dec 26: 19890-5
Prevalence of neutralizing antibodies against
adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis
and normal populations: Implications for gene therapy using AAV
vectors.
Human gene therapy
, 2006 Apr: 440-7
Use of Pseudomonas biofilm susceptibilities to assign
simulated antibiotic regimens for cystic fibrosis airway
infection.
The Journal of antimicrobial
chemotherapy
, 2005 Nov: 879-86
Standardized procedure for measurement of nasal potential
difference: an outcome measure in multicenter cystic fibrosis
clinical trials.
Pediatric pulmonology
, 2004 May: 385-92
Clinically feasible biofilm susceptibility assay for
isolates of Pseudomonas aeruginosa from patients with cystic
fibrosis.
Journal of clinical
microbiology
, 2004 May: 1915-22
Use of real-time PCR with multiple targets to identify
Pseudomonas aeruginosa and other nonfermenting gram-negative
bacilli from patients with cystic fibrosis.
Journal of clinical
microbiology
, 2003 Sep: 4312-7
Significant microbiological effect of inhaled tobramycin
in young children with cystic fibrosis.
American journal of respiratory and critical
care medicine
, 2003 Mar 15: 841-9
Analysis of sequential aliquots of hypertonic saline
solution-induced sputum from clinically stable patients with
cystic fibrosis.
Chest
, 2003 Mar: 792-9
Developing cystic fibrosis lung transplant referral
criteria using predictors of 2-year mortality.
American journal of respiratory and critical
care medicine
, 2002 Dec 15: 1550-5
Pseudomonas aeruginosa and other predictors of mortality
and morbidity in young children with cystic fibrosis.
Pediatric pulmonology
, 2002 Aug: 91-100